Bevacizumab and paclitaxel for breast cancer patients with CNS metastases

被引：1
|
作者：
Labidi, S. [1 ]
Bachelot, T. [1 ]
Coquard, I. L. Ray [1 ]
Favier, B. [1 ]
Galy, G. [1 ]
Guastalla, J. [1 ]
机构：
[1] Ctr Leon Berard, F-69373 Lyon, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.12009
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
12009
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases
    Xie, Yizhao
    Gong, Chengcheng
    Zhang, Jian
    Wang, Leiping
    Cao, Jun
    Tao, Zhonghua
    Li, Ting
    Zhao, Yannan
    Li, Yi
    Hu, Shihui
    Wang, Biyun
    Hu, Xichun
    BMC CANCER, 2021, 21 (01)
  • [42] Impact of CNS metastases on treatment and survival in patients receiving trastuzumab for metastatic breast cancer (MBC)
    Griffiths, R.
    Lindquist, K.
    Lalla, D.
    Doan, J. F.
    Brammer, M. G.
    Danese, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [43] Risk factors for outcome in Hispanic patients with breast cancer with central nervous system (CNS) metastases
    Schwarz, L. J.
    Vidaurre, T.
    Neciosup, S. P.
    Pinto, J. A.
    Ferreyros, G.
    Gomez, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [44] Phase II trial of nab-paclitaxel in metastatic breast cancer patients with visceral metastases
    Yizhao Xie
    Chengcheng Gong
    Jian Zhang
    Leiping Wang
    Jun Cao
    Zhonghua Tao
    Ting Li
    Yannan Zhao
    Yi Li
    Shihui Hu
    Biyun Wang
    Xichun Hu
    BMC Cancer, 21
  • [45] Genomic biomarkers of CNS-specific outcomes in patients with breast cancer brain metastases.
    Khatri, Ishaani S.
    Eichholz, Jordan
    Boe, Lillian A.
    Safonov, Anton
    Smith, Deborah Ruth
    Ferraro, Emanuela
    Shen, Junchao
    Imber, Brandon S.
    Yu, Yao
    Yamada, Yoshiya
    Miao, Emily
    Moss, Nelson S.
    Wilcox, Jessica
    Walch, Henry S.
    Chatila, Walid Khaled
    Schultz, Nikolaus
    Razavi, Pedram
    Pike, Luke R. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [46] PACLITAXEL-RESISTANT RECURRENT BREAST CANCER: A CASE OF PARTIAL RESPONSE DUE TO ADDITION OF BEVACIZUMAB TO PACLITAXEL
    Ishizuna, K.
    Kojima, M.
    Shimada, R.
    Aikawa, H.
    Okamura, T.
    Oya, M.
    ANNALS OF ONCOLOGY, 2013, 24
  • [47] Adding Bevacizumab to Paclitaxel in the First-Line Treatment of Metastatic Breast Cancer
    Fox, Kevin R.
    CURRENT ONCOLOGY REPORTS, 2009, 11 (01) : 5 - 6
  • [48] BEVACIZUMAB PLUS PACLITAXEL: AN EFFECTIVE AND SAFE SERVICE PROTOCOL FOR METASTATIC BREAST CANCER
    Jiveliouk, I.
    Grinberg, J.
    Inbar, M.
    ANNALS OF ONCOLOGY, 2009, 20 : 64 - 64
  • [49] Adding bevacizumab to paclitaxel in the first-line treatment of metastatic breast cancer
    Kevin R. Fox
    Current Oncology Reports, 2009, 11 : 5 - 7
  • [50] Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG)
    Pestalozzi, BC
    Zahrieh, D
    Price, KN
    Holmberg, SB
    Lindtner, J
    Collins, J
    Crivellari, D
    Fey, MF
    Murray, E
    Pagani, O
    Simoncini, E
    Castiglione-Gertsch, M
    Gelber, RD
    Coates, AS
    Goldhirsch, A
    ANNALS OF ONCOLOGY, 2006, 17 (06) : 935 - 944
12345